A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer

• Status: Completed
• Trial end date: 2007-11-01

Summary

The purpose of the study is to describe the tumor response rates for the two regimens being studied, and to determine how long patients live after receiving the treatment, how long patients are without return of their disease after they receive treatment, and how long the response they get from the treatment lasts. The amount and type of side effects/toxicities of each regimen will also be evaluated. The regimen including Oxaliplatin + 5FU/Folinic Acid is a current standard of care.

• Phase: Phase 2

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Bevacizumab; Fluorouracil; Folic Acid; Gemcitabine; Leucovorin; Levoleucovorin; Oxaliplatin